A ground-breaking stride has been made in leveraging omega-3 fatty acid derivatives to counteract visual impairments related to Alzheimer’s disease, diabetes, and other disorders.
Researchers have crafted a novel form of the omega-3 fatty acid docosahexaenoic acid (DHA) capable of permeating into the eye’s retina, presenting a potentially potent tool against degenerative visual decline.
Innovative Formulation for Effective Retinal Delivery
Traditional DHA found in supplements, known as triacylglycerol DHA (TAG-DHA), provides health benefits but faces a roadblock when it comes to reaching the eyes due to its inability to transition from the bloodstream into the retina.
To navigate this challenge, researchers developed a new lysophospholipid form of DHA, termed LPC-DHA, which, in mouse studies, effectively increased DHA levels in the retina and alleviated eye issues related to Alzheimer’s-like processes.
“Dietary LPC-DHA robustly surpasses TAG-DHA in augmenting retinal DHA, and unveils a prospective benefit for various retinopathies,” comments Sugasini Dhavamani, a research assistant professor at the University of Illinois at Chicago.
He emphasizes the innovation’s potential in thwarting or mitigating retinal dysfunction associated with diseases like Alzheimer’s and diabetes.
This novel approach will be presented at the Discover BMB meeting, hosted by the American Society for Biochemistry and Molecular Biology.
Spotlight on DHA: Ensuring Optimal Visual Health
Healthy eyes boast a rich concentration of DHA in the retina, pivotal for sustaining photoreceptors which transduce light into neural signals dispatched to the brain.
A deficiency of DHA in the retina is correlated with vision loss, an affliction frequently encountered by individuals grappling with Alzheimer’s disease, diabetes, retinitis pigmentosa, age-related macular degeneration, and peroxisomal disorders, often culminating in conspicuous reductions in retinal DHA and resultant visual impairments.
The pathway to enriching retinal DHA content has been fraught with challenges due to the necessity for DHA to be absorbed from the intestine into the bloodstream and subsequently traverse from the bloodstream into the retina.
Dhavamani highlights the unique potency of dietary LPC-DHA, which effectively surmounts both the intestinal and blood-retinal barriers, thereby enhancing retinal function.
A Glimpse into Future Potential: Early Positive Outcomes in Mice
Subjected to a six-month testing regime, mice, genetically engineered to exhibit early-onset Alzheimer’s disease-like processes and fed LPC-DHA daily, demonstrated a significant 96% improvement in retinal DHA content alongside preserved retinal structure and functionality.
Conversely, TAG-DHA supplementation proved ineffectual in altering retinal DHA levels or functionality.
These findings illuminate the potential efficacy of LPC-DHA supplements in safeguarding against visual function declines linked with Alzheimer’s and other disorders characterized by DHA deficiency and vision impairment.
However, further investigations will be instrumental in validating the safety and efficacy of LPC-DHA in human applications.
While additional studies are requisite, this research signals a potentially transformative approach in managing and possibly mitigating visual decline across a spectrum of disorders.
The derivative, LPC-DHA, with its ability to effectively navigate biological barriers and enrich retinal DHA, could pave the way toward innovative therapeutic strategies, potentially illuminating a brighter future for those facing the dimming light of visual impairment.
If you care about Alzheimer’s, please read studies about the likely cause of Alzheimer’s disease , and new non-drug treatment that could help prevent Alzheimer’s.
For more information about brain health, please see recent studies about diet that may help prevent Alzheimer’s, and results showing some dementia cases could be prevented by changing these 12 things.
Follow us on Twitter for more articles about this topic.
Copyright © 2023 Knowridge Science Report. All rights reserved.
